Cargando…

S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA

Detalles Bibliográficos
Autores principales:	Locatelli, Franco, Lang, Peter, Corbacioglu, Selim, LI, Amanda, De La Fuente, Josu, Wall, Donna, Meisel, Roland, Shah, Ami J., Liem, Robert, Mapara, Markus, Carpenter, Ben, Kwiatkowski, Janet, Domenica Cappellini, Maria, Kattamis, Antonis, Sheth, Sujit, Grupp, Stephan, Kohli, Puja, Shi, Daoyuan, Ross, Leorah, Bobruff, Yael, Simard, Christopher, Zhang, Lanju, Khanh Morrow, Phuong, Hobbs, Bill, Frangoul, Haydar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428247/ http://dx.doi.org/10.1097/01.HS9.0000967992.84731.80

Ejemplares similares

5612617 EFFICACY AND SAFETY OF A SINGLE DOSE OF EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT-THALASSEMIA AND SEVERE SICKLE CELL DISEASE
por: de la Fuente, J., et al.
Publicado: (2023)

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
por: Kansal, Anuraag R., et al.
Publicado: (2021)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
por: Porter, John B., et al.
Publicado: (2016)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

Zynteglo: Betibeglogene autotemcel – An innovative therapy for β- thalassemia patients
por: Asghar, Adam Ali, et al.
Publicado: (2022)

P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
por: Kuo, K, et al.
Publicado: (2022)

Does Splenectomy Influence the Development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A Retrospective Study
por: Skafida, Myrto, et al.
Publicado: (2019)

Transfusion trigger: when to transfuse?
por: Marshall, John C
Publicado: (2004)

To transfuse or not to transfuse: thinking outside the box
por: Sakr, Yasser, et al.
Publicado: (2010)

Massive transfusion and massive transfusion protocol
por: Patil, Vijaya, et al.
Publicado: (2014)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management
por: Sleiman, Joseph, et al.
Publicado: (2018)

Transfusion
Publicado: (1889)

Transfusion
Publicado: (1878)

Transfusion
Publicado: (1875)

Transfusion
Publicado: (1874)

Transfusion
por: Soden, John
Publicado: (1854)

P1741: EXAMINING THE BURDEN OF ILLNESS ASSOCIATED WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA FROM THE PATIENT’S PERSPECTIVE
por: Knoth, R. L., et al.
Publicado: (2022)

Impact of Transfused Citrate on Pathophysiology in Massive Transfusion
por: Schriner, Jacob B., et al.
Publicado: (2023)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023)

Marital status and paternity in patients with Transfusion-Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries
por: De Sanctis, Vincenzo, et al.
Publicado: (2019)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Transfusion Risks and Transfusion-related Pro-inflammatory Responses
por: Despotis, George John, et al.
Publicado: (2007)

P1517: REAL-WORLD COMPLICATION BURDEN AND DISEASE MANAGEMENT IN TRANSFUSION-DEPENDENT ADULTS WITH ΒETA-THALASSEMIA (Β-THAL) IN GREECE: FINAL RESULTS OF THE EPIDEMIOLOGICAL CROSS-SECTIONAL ULYSSES STUDY
por: Kattamis, A., et al.
Publicado: (2022)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Blood Transfusion
Publicado: (1950)

Transfusion of Blood
Publicado: (1919)

Transfusion of Blood
por: Porter, J. W.
Publicado: (1921)

Plasma Transfusion
Publicado: (1941)

The Transfusion of Life
Publicado: (1912)

Blood Transfusion
Publicado: (1951)

Transfusion of Blood
Publicado: (1889)

Case of Transfusion
por: Lister,
Publicado: (1869)

Case of Transfusion
por: Philpott, R. P.
Publicado: (1827)

Cannot write session to /tmp/vufind_sessions/sess_t1lr1pgl9k6ougmalj6ne8ebnp